Johnson & Johnson
What analysts say:
- Buy, sell, or hold?: The majority of analysts back Johnson & Johnson as a buy. But with 52.4% of analysts rating it a buy, Johnson & Johnson is still below the mean analyst rating of its nearest 10 competitors, which average 53.5% buys. Analysts don't like Johnson & Johnson as much as competitor Pfizer overall. Fifteen out of 16 analysts rate Pfizer a buy compared to 11 of 21 for Johnson & Johnson. Analysts' rating of Johnson & Johnson has stayed constant from three months prior.
- Revenue Forecasts: On average, analysts predict $16.02 billion in revenue this quarter. That would represent a rise of 6.9% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.21 per share. Estimates range from $1.16 to $1.30.
What our community says:
CAPS All Stars are solidly backing the stock with 98.2% awarding it an "outperform" rating. The community at large concurs with the All Stars with 96.5% granting it a rating of "outperform." Fools are keen on Johnson & Johnson and haven't been shy with their opinions lately, logging 3,278 posts in the past 30 days. Johnson & Johnson has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Johnson & Johnson's income has fallen year over year by an average of 13.1% over the past five quarters. The company's revenue has now risen for two straight quarters.
One final thing: If you want to keep tabs on Johnson & Johnson movements, and for more analysis on the company, make sure you add it to your Watchlist.
The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?
Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)
It's a close contest, but there is one deciding factor.
3 Dividend Stocks Ideal for Retirees
Find out why these three stocks are a perfect fit for investors looking to boost their income stream.